NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing

BETHESDA, Md., May 1, 2015 /PRNewswire/  Northwest Biotherapeutics (NASDAQ: NWBO) ( NW Bio ), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has closed on the $28.5 million second tranche of a $40 million investment from Woodford investment funds in the UK ( Woodford ). Woodford first invested $25 million in NW Bio on November 19, 2014.  On April 2, 2015, Woodford entered into an agreement with the Company for a further $40 million investment in two tranches ($11.5 million and $28.5 million).  Both of these tranches have been completed in accordance with the agreement.  Woodford has also made substantial open market purchases of NW Bio shares, as reflected in the investment positions publicly reported on the Woodford funds website. Strong science and solid financing are keys to our continuing progress at the forefront of immune therapies for cancer,  Linda Powers, CEO of NW Bio


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: